Management of Vomiting During Oxaliplatin Infusion
If vomiting occurs during oxaliplatin infusion, immediately interrupt the infusion and administer rescue antiemetics from a different drug class than what was used for prophylaxis, preferably via intravenous or rectal route rather than oral. 1
Immediate Actions
When breakthrough vomiting occurs during infusion:
- Stop the infusion immediately - Do not continue administering oxaliplatin while the patient is actively vomiting
- Switch to parenteral rescue therapy - The oral route is not feasible during active vomiting; use IV or rectal administration 1
- Administer an agent from a different drug class than what was given for prophylaxis 1
Rescue Medication Options
Consider these agents for breakthrough emesis (no single agent is superior):
- Dopamine antagonists: Metoclopramide (20-30 mg IV) or haloperidol 1, 2
- Corticosteroids: Dexamethasone (if not already maximized) 1
- Benzodiazepines: Lorazepam 0.5-2 mg IV/sublingual 1
- Multiple concurrent agents may be necessary, potentially in alternating schedules 1
Strongly consider around-the-clock dosing rather than PRN administration to prevent recurrence 1.
Supportive Care
- Ensure adequate hydration and check/correct electrolyte abnormalities immediately 1
- Assess for non-chemotherapy causes: Brain metastases, bowel obstruction, other GI abnormalities 1
- Consider antacid therapy (H2 blocker or proton pump inhibitor) if dyspepsia is present, as patients may confuse heartburn with nausea 1
Decision to Resume or Discontinue Infusion
Once vomiting is controlled:
- Evaluate whether to resume the current infusion based on:
- Time elapsed and dose already administered
- Severity and duration of the vomiting episode
- Patient's overall clinical status
- Whether this represents a hypersensitivity reaction versus breakthrough emesis
Important distinction: Oxaliplatin can cause acute cholinergic syndrome with emesis during/after infusion, which differs from hypersensitivity reactions 3. True hypersensitivity reactions require permanent discontinuation.
Prevention for Next Cycle
Before the next oxaliplatin cycle, reassess the antiemetic regimen that failed:
For oxaliplatin (moderately emetogenic), the standard prophylaxis should include 4, 5:
- Day 1: Palonosetron (preferred 5-HT3 antagonist) + dexamethasone
- Days 2-3: Dexamethasone continuation
If breakthrough occurred despite standard prophylaxis, consider 1, 6:
- Adding an NK1 receptor antagonist (aprepitant 125 mg day 1, then 80 mg days 2-3) to the regimen
- Adding prophylactic dopamine antagonists (metoclopramide) or haloperidol
- Switching to a different 5-HT3 antagonist (though evidence for benefit is limited)
- Adding lorazepam for anticipatory component
Common Pitfall
Do not assume adequate prophylaxis was given initially. Studies show 54% of patients experience delayed nausea/vomiting after oxaliplatin when only day 1 prophylaxis is provided 7. Oxaliplatin causes significant delayed emesis requiring multi-day antiemetic coverage 7, 8.
The evidence demonstrates that complete response rates drop from 90% in the first 24 hours to only 54% in the delayed period (days 2-5) without continued prophylaxis 7, emphasizing the need for scheduled antiemetics beyond day 1.